Objective: We investigated the effects of whey protein (WP), pea protein hydrolysate (PPH), a combination of WP þ PPH and control (milk protein (MP) which consists of 80% casein and 20% WP) on appetite ratings, postprandial changes in hunger/ satiety hormones and energy intake (EI). Design: A randomized, crossover design which consisted of 2 parts (experiment 1 and 2). The peptides to be tested were provided as part of a shake (1024 kJ; en% P/F/C: 25/33/42) which contained either 15 g WP, 15 g PPH, a combination of 7.5 g WP and 7.5 g PPH (WP þ PPH) or 15 g MP. Subjects: 39 subjects (BMI: 27.6 ± 1.7 kg m À2 ; age: 42.3 ± 13.8 years). Measurements: In experiment 1 (duration 4 h), appetite profile was measured and blood samples were taken for analysis of hunger/satiety hormones and glucose. In experiment 2 (duration 7 h), appetite profile and EI (180 min after consumption of the shake) were measured. Results: Some indications of lower hunger (experiment 1), desire to eat (experiment 2) and thirst (experiment 1 and 2) were shown after consumption of PPH compared to MP or WP þ PPH (Po0.05). A longer intermeal interval and a higher satiety index were suggested after consumption of PPH. Both PPH and WP lead to greater satiety (experiment 2) and fullness (experiment 2) compared to MP and WP þ PPH (Po0.05). For WP, a positive correlation between insulin and both cholecystokinine (CCK) and glucagon like peptide-1 (GLP-1) was observed (Po0.05). However, both CCK and GLP-1 were increased by MP (Po0.05), peptide YY (PYY) was stimulated by WP þ PPH, while the decline in ghrelin was larger (Po0.05). No effect on EI was seen. Conclusion: There was modest evidence with respect to satiety by PPH consumption. Different exogenous biopeptides produced differences in release of endogenous peptides that had inconsistent relationships with satiety. Therefore, evidence derived from a supposed biomarker for satiety does not guarantee the highest satiety.
Introduction
Protein has been observed to have a more satiating effect than carbohydrate and fat and can therefore reduce energy intake (EI). 1, 2 The protein source may be a determinant of the satiating efficacy of protein, but very limited data from studies in humans exist on this topic, and the available evidence is inconsistent. [3] [4] [5] [6] [7] [8] [9] Higher satiety ratings were found over a 3 h period when young men were fed a 50 g meal of lean fish compared to an equivalent amount of either beef or chicken. 7 Other research showed that 48 g whey increased satiety ratings and decreased EI more than 48 g casein at a buffet meal consumed 90 min later by healthy volunteers. 4 In addition, whey consistently resulted in the greatest EI suppression, decreased EI relative to control and sucrose, as well as in comparison with egg albumin and soy protein in young men. 8 In contrast, other studies found no difference in EI after consumption of different types of protein. 5, 6, 9 The mechanisms by which the peptide products of protein digestion exert their effect on EI via the gastrointestinal tract may include stimulation of satiety or anorexigenic hormones such as glucagon like peptide-1 (GLP-1), cholecystokinine (CCK), peptide YY (PYY) or inhibition of the putative 'orexigenic' hormone ghrelin (Ghr). 3, 10 Postprandial changes in the plasma concentrations of these hormones appear to be partially macronutrient specific (and possibly protein source specific) and may therefore contribute to differences in satiety. [11] [12] [13] [14] [15] [16] [17] [18] [19] In the present study, we investigated the satiating effects of pea protein hydrolysate (PPH) and whey protein (WP), based upon in vitro high throughput CCK analysis 20 and a rat study in which PPH and WP showed the highest EI reduction and were speculated to have an even more pronounced effect, if administered together (personal communication Doreen Häberer, 2006) . The aims of this study were to examine the effects of WP, PPH, a combination of WP and PPH and control (milk protein (MP) which consists of 80% casein and 20% WP) on appetite ratings and postprandial changes in plasma Ghr, GLP-1, CCK and PYY (experiment 1) in human. Furthermore, in a second experiment, we assessed whether a possible appetite effect is reflected in the subsequent meal size.
Methods
Subjects Thirty-nine overweight subjects (20 females, 19 males), aged 18-60 years and with a BMI between 25 and 31 kg m À2 participated in this study. The subjects were recruited by advertisements in local newspapers. All subjects participated in an initial screening that involved measurement of body weight, height, body composition, waist/hip circumference, blood pressure as well as heart rate and included completion of a questionnaire related to eating behavior (Three Factor Eating Questionnaire; TFEQ 21 ) and completion of a questionnaire related to health, use of medication, smoking behavior, alcohol consumption and physical activity. All subjects were in good health, nonsmokers, not using medication, at most moderate alcohol users and unrestrained eaters (as assessed by factor 1 of the TFEQ). Baseline characteristics of the subjects are presented in Table 1 .
The subjects gave their written informed consent and the Medical Ethical Committee of Maastricht University approved the study.
Experimental design
The study had a randomized, single-blind, crossover design and consisted of two parts (experiment 1 and experiment 2). Each subject participated in the two separate experiments and each experiment had a crossover design. In both experiments 1 and 2, subjects attended the university laboratory on four occasions with 1 week between visits. On each occasion, subjects arrived after fasting overnight. Body weight was measured on the first occasion of each experiment.
In experiment 1, an intravenous catheter was inserted and a fasting blood sample was taken. Subjects then completed an appetite and tolerance questionnaire (see 'Questionnaires' section). A shake (for composition see 'dietary protocol') and 150 ml water were consumed at time 0. The shakes were served in randomized order and consumed within 5 min. Subsequent blood samples were collected 30, 60, 90 and 120 min after time 0. An appetite questionnaire was completed 30, 60, 90, 120, 180 and 240 min after consumption of the shake, taking care that completing questionnaires was not affected by taking blood samples. At timepoint 240, subjects completed a tolerance questionnaire and left the university laboratory.
The results of the appetite questionnaire from experiment 1 were used to decide at which timepoint subjects were offered a lunch in experiment 2.
In experiment 2, subjects completed an appetite and tolerance questionnaire. A shake and 150 ml water were consumed at time 0. The shakes were served in randomized order and consumed within 5 min. Subsequent appetite questionnaires were completed 30, 60, 90, 120 and 180 min after consumption of the shake. At timepoint 180 (as decided on the base of the results of experiment 1), subjects were offered an ad libitum lunch and 300 ml water. Instructions were given to eat until comfortably satiated. Food was removed after 20 min. Five and 60 min after lunch, subjects completed the appetite questionnaire. Sixty minutes after lunch, subjects completed a tolerance questionnaire, left the university laboratory and were instructed not to eat or drink at home, except water, till 240 min after lunch and to complete the appetite questionnaire at 120, 180 and 240 min after lunch.
Dietary protocol
The peptides to be tested were provided as part of a 300 ml shake (1024 kJ; 25% of total energy from protein, 33% from fat and 42% from carbohydrate) which contained either 15 g WP, 15 g PPH (provided by DSM Food Specialties, Delft, The Netherlands), a combination of 7.5 g WP and 7.5 g PPH (WP þ PPH) or 15 g MP (control). MP consists of 80% casein ) and macronutrient composition. Hedonic value of the shakes was sufficient (45.5 on a 10-point scale), without any differences between the peptides.
The ad libitum lunch in experiment 2 consisted of Turkish bread, spread with egg salad (1137 kJ per 100 g; 13% of total energy from protein, 46% from fat and 41% from carbohydrate). Food was weighed prior to the meal and after the subjects left the laboratory. Food intake was assessed by difference.
Anthropometry
Body weight was measured using a digital balance accurate to 0.02 kg (Chyo-MW-150K, Chyo, Japan) with subjects in underwear after voiding their bladder. Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. The waist/hip ratio was calculated by dividing the waist circumference by the hip circumference. The waist circumference was measured at the site of the smallest circumference between the rib cage and the iliac crest, and the hip circumference was measured at the site of the largest circumference between the waist and the thighs. Both measurements were performed with subjects in standing position. Systolic blood pressure, diastolic blood pressure and heart rate were recorded using an automatic blood pressure monitor (OSZ 5 easy; Spreidel & Keller GmBH and Co. KG, Jungingen, Germany). Body composition was measured using the 2 H 2 O dilution technique.
22-24

Questionnaires
The appetite questionnaire is a Visual Analogue Scale questionnaire (VAS, in mm) with questions about feelings of hunger, fullness, satiety, thirst and desire to eat. 25 Opposing extremes of each feeling were described at either end of a 100-mm horizontal line, and subjects marked the line to indicate how they felt at that moment.
Tolerance was determined using a questionnaire on the occurrence of complaints (headache, nausea, stomachache, diarrhea and so on) and scored. 26 Frequency classification was 0, never; 1, seldom; 2, sometimes; 3, relatively often; 4, often (5-point scale).
Blood parameters
Blood samples were collected for analysis of GLP-1, CCK, PYY, Ghr, insulin and glucose. The blood samples were mixed with ethylenediaminetetraacetic acid (EDTA) to prevent clotting. Samples for GLP-1 (4 ml) and PYY analysis (4 ml) were mixed with 40 ml of a dipeptidyl peptidase IV (DPP-IV) inhibitor (Linco Research Inc., St Charles, MO, USA) to prevent degradation. Samples for CCK (4 ml) and PYY analysis (4 ml) were mixed with 2000 KIU Trasylol (Bayer Diagnostics Europe Ltd, Mijdrecht, The Netherlands). Plasma was obtained by centrifugation (4 1C, 1500 g, 10 min), frozen in liquid nitrogen and stored at À80 1C until further analysis. Plasma Ghr samples were mixed with HCl, methanol and phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich, Zwijndrecht, The Netherlands). Glucose concentrations were determined using the hexokinase method (Glucose HK 125 kit, ABX diagnostics, Montpellier, France). Plasma concentrations of insulin, active Ghr and PYY3-36 were measured by RIA (Linco Research Inc.). Plasma active GLP-1 samples were analyzed using ELISA (EGLP-35K; Linco Research Inc.). CCK was determined using RIA (Euria-CCK, Euro-Diagnostica AB, Malmö, Sweden).
Statistical analysis
Data are presented as means ± standard deviations, unless otherwise indicated. Data were analyzed using Statview SE þ Graphics (Abacus Concepts, Berkeley, CA, USA, 1988) and using SPSS 14 (SPSS Inc., Chicago, IL, USA). A one-factor repeated measures ANOVA was used to determine possible differences between the conditions. For the appetite ratings of experiment 1, also an ANCOVA with the baseline values as covariate was used to determine possible differences between the conditions. Correction for multiple comparisons was applied. Post hoc, a Scheffe F-test was executed to locate the differences. Univariate linear regression was used to determine possible relationships between selected variables at timepoints when the different data were both available. Area under the curve (AUC) was calculated as incremental area under the curve over time, using the trapezoidal method. 27 The level for establishing significant differences was taken at Po0.05.
Results
The baseline values of all measured variables were not significantly different between treatments. 
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Body weight (kg) was not different between the first occasion of experiment 1 (82.5±9.8) and experiment 2 (82.3 ± 9.8). In both experiments 1 and 2, tolerance was not significantly different between the shakes (data not shown).
The hunger scores (experiment 1) of the appetite questionnaire are shown in Figures 1a and b . Post hoc tests showed that 90 min after consumption of the shakes, significantly less hunger was reported after PPH, compared to MP (Po0.05). Furthermore, an overall significant difference was found 240 min after consumption of the shakes with significantly less hunger after consumption of shake PPH compared to WP (Po0.05). As presented in Figure 1b , the AUC for hunger was significantly smaller for PPH compared to WP þ PPH (Po0.05). In addition, the intermeal interval (min) was estimated. The intermeal interval is the time elapsed between consumption of the shake and the point at which hunger scores returned to baseline. As shown in Table 3 , the hunger scores of the four groups returned to baseline between 90 and 120 min and the longest intermeal interval was observed for PPH. Due to the large variation between subjects, a statistical analysis of the intermeal interval was not useful.
Based on the overall significant difference in hunger ratings at 240 min and the intermeal interval between 90 and 120 min, we decided to provide the lunch in experiment 2, 180 min after consumption of the shakes.
Subjects were less thirsty 60 min after consumption of the shake containing PPH (À11.0 ± 22.5) compared to the shake containing MP (À3.8±24.4) (Po0.05). No significant differences were seen for satiety, fullness and desire to eat (data not shown).
Using the ANCOVA (not shown in figures) with the baseline values as covariate, less hunger was reported 240 min after consumption of PPH compared to WP (Po0.05). In addition, a greater satiety and fullness was observed 180 min after consumption of PPH compared to MP (Po0.05).
The blood parameter results are presented in Figures 2a (glucose), 2b (GLP-1), 2c (CCK), 2d (PYY), 2e (Ghr) and Table 4 (AUC of these variables). No significant differences were seen for insulin (data not shown). Consumption of the WP, PPH or WP þ PPH shakes caused, determined as AUC, a lower CCK and/or GLP-1 concentration compared to MP (Table 4 , Po0.05). At separate timepoints (30, 60, 90 or 120 min) the WP, PPH or WP þ PPH shakes caused higher plasma concentrations of glucose, and lower concentrations of GLP-1 and CCK (Figures 2a-c, Po0.05) . However, at 30 min, PYY concentrations were higher after WP þ PPH compared to MP and the other shakes (Figure 2d , Po0.05). At 120 min, Ghr concentrations were lower after WP þ PPH compared to MP (Figure 2e, Po0.05) .
Only in the WP condition, hunger and satiety were respectively negatively and positively correlated with PYY (time 60-0: r 2 ¼ 0.11, resp r 2 ¼ 0.2, Po0.05). 
In experiment 2, 180 min after consumption of the shakes, no difference in food intake (g) at lunch was seen between the four groups (WP 299.9 ± 98.2; PPH 304.2 ± 106.6; WP þ PPH 309.0±115.0; MP 303.5±115.4).
In experiment 2, no significant differences were seen for hunger (data not shown). Figures 3a (satiety) , 3b (fullness), 3c (desire to eat) and 3d (thirst) show the appetite scores from experiment 2. PPH consumption was followed by Here the smaller desire to eat is most remarkable. This coincides with the longer estimated intermeal interval after PPH consumption (Table 3 ). WP consumption was followed by a greater satiety or fullness (at 30 or 90 min after shake, or 60 min after lunch) compared to MP or WP þ PPH (Figures 3a  and b , Po0.05). WP þ PPH did not show remarkable effects compared to MP. When a satiety index (AUC satiety after lunch/EI in kJ) was calculated for the different shakes (WP: 2.9 ± 1.9; PPH: 3.2 ± 2.4; WP þ PPH: 2.5 ± 2.1; MP: 2.5 ± 3.0), a trend (P ¼ 0.09) was observed for a greater index for PPH compared to WP þ PPH. 
Discussion
Based on appetite ratings, PPH and to a lesser extent WP are considered as most effective in suppressing hunger and stimulating satiety relative to whole MP. However, this finding is not supported by the observed changes in concentrations of the satiety hormones and Ghr. Both CCK and GLP-1 are more stimulated by MP than by the other shakes and PYY is stimulated in particular by WP þ PPH, which also caused a less pronounced decrease in postprandial Ghr concentration.
This study shows that consumption of a 1 MJ PPH shake caused less hunger (experiment 1), less desire to eat (experiment 2) and less thirst (experiment 1 and 2) prior to the next meal (preprandial effect). With respect to the postprandial effect of the 1 MJ shakes on fullness and satiety, both PPH and WP caused greater satiety (experiment 2) and fullness (experiment 2) compared to MP and WP þ PPH. Furthermore, a longer intermeal interval and greater satiety index appeared to occur after consumption of the PPH shake.
The effects of the shakes on the changes in plasma concentrations of the hormones do not support the findings from the appetite ratings. 120 min after consumption of WP þ PPH, a lower concentration of the hunger hormone Ghr was seen compared to MP although both groups displayed similar hunger and satiety. In addition, 30 min after consumption of WP þ PPH, a higher PYY concentration, but not greater satiety, was seen compared to the other shakes. No significant differences were seen on other timepoints. Presumably because the liquid meal (shake) was ingested within a short space of time, PYY concentration peaked already at 30 min after WP þ PPH ingestion. 28 In humans, PYY reduces Ghr so the decreased Ghr with WP þ PPH may be a reflection of this. 29 Both CCK and GLP-1 reached higher concentrations after MP consumption than after the other shakes. MP consists of casein and WP (casein makes up about 80% of the protein in cow's milk, while the remaining 20% of protein in milk is whey). The digestion and absorption of whey and casein differ in that casein, unlike whey, coagulates in the stomach due to its precipitation by gastric acid. 4, 30, 31 As a result, overall gastric emptying time for casein is longer. The concept of 'fast' and 'slow' proteins was introduced by Boirie et al. 32 to describe these differences in digestion and absorption of whey and casein. The 'fast' whey may cause a fast peak and the 'slow' casein brings about a prolonging effect. The unique combination of both whey and casein in MP may therefore explain the high CCK and GLP-1 concentrations observed after consumption of the MP shake. For WP, a positive correlation between insulin and both CCK and GLP-1 was seen. For WP þ PPH, a positive correlation between insulin and CCK was observed. Previous studies reported differences in plasma insulin concentrations following different meal proteins. 5, 33 Whey contains high concentrations of branched chain amino acids (leucine, isoleucine and valine), and it has been suggested that these amino acids have a unique metabolic role, possibly enhancing satiety due to extra-hepatic metabolism and interactions with insulin signaling pathways. 34, 35 Despite the differences between shakes in appetite ratings and satiety hormones, no effect on EI during the subsequent lunch was seen. A remark is that the differences in appetite scores at 180 min may have been too small to get differences in EI (personal communication Margriet Veldhorst, 2007). Similarly, Lang et al. 5, 6, 9 concluded that varying the protein source does not affect ingestive behavior in healthy humans. In contrast, other research showed differences in EI after consumption of different types of protein. 4, 8 A general explanation for the postprandial effects instead of preprandial effects may be that the parameters characterizing the postprandial meal interval are correlated with the meal size and characteristics. 36 People eat in an anticipating way, to bridge the following meal interval. Thus meal size is likely to be less affected by preprandial interventions, yet it affects postprandial parameters. Only when the preprandial triggers differ very substantially, meal size may be affected. Furthermore, it has been suggested that the meal size of 1 MJ may have been small, yet in other studies it appeared to be large enough to cause differences in EI. 37 The appetite ratings of experiment 1 were analyzed with both ANOVA repeated measures (analysis of change score) and ANCOVA with the baseline values as covariate. There is continuing discussion regarding the conditions under which these different approaches are most appropriate. 38 In this study, the use of ANCOVA with baseline values as covariates led to less apparent differences in treatments.
In conclusion, when ingested, different exogenous biopeptides cause differences in the release of endogenous peptide hormones that may have inconsistent relationships with satiety. When peptides such as whey trigger successively insulin, GLP-1 and CCK release, this does not guarantee a stronger satiety effect nor is it always correlated with a perceived satiety effect. There was modest evidence with respect to satiety enhancement for PPH consumption, in terms of hunger, satiety, desire to eat and the suggested longer intermeal interval and the trend for a higher satiety index. Nevertheless, where greater satiety responses were seen with PPH, they did not reflect strong correlations of selfreported satiety with proposed satiety hormones. Thus with respect to effects of exogenous and endogenous peptides, a supposed biomarker for satiety does not guarantee the highest satiety.
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